#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Partial lipodystrophy Hepatic angiosarcoma B-cell small lymphocytic lymphoma recurrent Desmoid tumour Undifferentiated sarcoma Activated PI3 kinase delta syndrome Rhabdomyosarcoma recurrent Thrombocytosis Transferrin decreased Retinoblastoma Osteosarcoma recurrent Fragile X syndrome Progressive familial intrahepatic cholestasis Ductal adenocarcinoma of pancreas Hereditary spastic paraplegia More trials…

    Learn about Rare Diseases

    Waldenstrom’s macroglobulinaemia refractory – Trials in Disease Medulloblastoma recurrent – Treatment Bronchiolitis obliterans syndrome – Basic Information Pemphigoid – Trials in Disease Idiopathic pulmonary fibrosis – Diagnostics Acquired haemophilia – Diagnostics Focal segmental glomerulosclerosis – Treatment Methylmalonic acidaemia – Treatment Gastrointestinal stromal tumour – Basic Information Undifferentiated sarcoma – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Dexamethasone Isonicotinate Ladarixin Antipsychotics Mva-209-Fsp-B1 Xylitol Iodixanol Montelukast FOSFOMYCIN CALCIUM Elraglusib Fluoroethyltyrosine F-18 Immunoglobulin A Ketoprofen Dersimelagon Phosphate Acetylsalicylic Acid Ph. Eur. Ethanol, Anhydrous Norucholic Acid Mirtazapine Selinexor GT-002 Autologous Pancreatic Islets More therapies…

    Learn about Your Condition

    Ear discomfort Metastatic glioma Lung transplant Pelizaeus-Merzbacher disease Inner ear disorder Cryoglobulinaemia Oesophageal disorder Cartilage injury Supranuclear palsy Delayed graft function Myasthenia gravis Hereditary optic atrophy Alport's syndrome Mesothelioma Cortisol abnormal More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • Study on the Early Use of Risdiplam for Children with Spinal Muscular Atrophy After Gene Therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Spinal muscular atrophy
    Investigated Drugs:
    • Risdiplam
    Germany Poland

  • Study on the Safety and Effectiveness of Rebisufligene Etisparvovec for Patients with Mucopolysaccharidosis Type IIIA

    Recruiting

    2 1 1
    Investigated Drugs:
    • Rebisufligene Etisparvovec
    Spain

  • Long-term safety study of rebisufligene etisparvovec gene therapy in patients previously treated for Mucopolysaccharidosis type IIIA

    Recruiting

    3 1 1
    Investigated Diseases:
    • Mucopolysaccharidosis III
    Investigated Drugs:
    • Rebisufligene Etisparvovec
    Spain

  • Study on the Safety and Tolerability of Treprostinil Sodium for Children with Pulmonary Arterial Hypertension

    Recruiting

    3 1 1
    Investigated Drugs:
    • Treprostinil Sodium
    Austria France Germany Hungary Slovakia Spain

  • Long-Term Follow-Up Study for Patients Treated with CAR T-Cell Therapy Using PHE885, YTB323, and Tisagenlecleucel

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • B-cell lymphoma
    • B-cell type acute leukaemia
    • Plasma cell myeloma
    Investigated Drugs:
    • Autologous T-Cells Encoding A Chimeric Antigen Receptor Targeting Human B Cell Maturation Antigen
    • Rapcabtagene Autoleucel
    • Tisagenlecleucel
    Austria Belgium Denmark Finland France Germany +6

  • Study on Bevacizumab, Encorafenib, and Cetuximab for Patients with BRAF-V600E Mutated Metastatic Colorectal Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Encorafenib
    • Bevacizumab
    • Cetuximab
    Spain
Previous Page
1 … 434 435 436 437 438 … 1,651
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!